Subtype-specific circadian clock dysregulation modulates breast cancer biology, invasiveness, and prognosis.
Breast Cancer
Circadian Data Ordering
Circadian Medicine
Estrogen Receptor
Informatics
Metastasis
Prognosis
Rhythm Strength
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
19 May 2023
19 May 2023
Historique:
pubmed:
9
6
2023
medline:
9
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Studies in shift workers and model organisms link circadian disruption to breast cancer. However, molecular rhythms in non-cancerous and cancerous human breast tissues are largely unknown. We reconstructed rhythms informatically, integrating locally collected, time-stamped biopsies with public datasets. For non-cancerous tissue, the inferred order of core-circadian genes matches established physiology. Inflammatory, epithelial-mesenchymal transition (EMT), and estrogen responsiveness pathways show circadian modulation. Among tumors, clock correlation analysis demonstrates subtype-specific changes in circadian organization. Luminal A organoids and informatic ordering of Luminal A samples exhibit continued, albeit disrupted rhythms. However, CYCLOPS magnitude, a measure of global rhythm strength, varied widely among Luminal A samples. Cycling of EMT pathway genes was markedly increased in high-magnitude Luminal A tumors. Patients with high-magnitude tumors had reduced 5-year survival. Correspondingly, 3D Luminal A cultures show reduced invasion following molecular clock disruption. This study links subtype-specific circadian disruption in breast cancer to EMT, metastatic potential, and prognosis.
Identifiants
pubmed: 37293090
doi: 10.1101/2023.05.17.540386
pmc: PMC10245642
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG068577
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227485
Pays : United States
Déclaration de conflit d'intérêts
Declaration of interests J.B.H. is on the scientific advisory board for Synchronicity Pharma. The remaining authors declare no competing interests.